US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

CytoMed Therapeutics Limited

1.08

+0.230127.07%

Post-market: 1.110.0299+2.77%19:09 EST

Volume:21.99M

Turnover:25.02M

Market Cap:12.67M

PE:-4.32

High:1.25

Open:1.04

Low:0.9012

Close:0.8499

52wk High:3.68

52wk Low:0.7282

Shares:11.73M

Float Shares:5.99M

Volume Ratio:10.71

T/O Rate:367.25%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.2499

EPS(LYR):-0.1598

ROE:-42.33%

ROA:-22.85%

PB:2.26

PE(LYR):-6.76

Loading ...

Overview Company News Filings

CytoMed Therapeutics Refutes Misleading Claims and Reaffirms Clinical Progress

Cytomed sees ‘enough resources’ to continue activites for ‘at least a year’

Cytomed Therapeutics Reports Sufficient Funding and Advances Clinical Trials for Cancer Therapies

CytoMed Therapeutics’ new year update and seeks shareholders’ feedback on proposal to improve shareholder value for their patient capital

CytoMed Therapeutics Partners with Universiti Malaya Medical Centre for First-In-Human Gamma Delta T Cell Cancer Trial

CytoMed completes acquisition of T cell technology of TC BioPharm

Press Release: CytoMed Therapeutics Completes Acquisition of T Cell Technology from UK to Treat Cancers in China and India

CytoMed Therapeutics Secures $500,000 Investment for LongevityBank Subsidiary

CytoMed Therapeutics Granted Patent for Gamma Delta T Cell Technology by China National Intellectual Property Administration

Press Release: CytoMed Therapeutics Secures Non-Dilutive Investment for Subsidiary LongevityBank from ICH Capital and Updates on New China Strategy

CytoMed Therapeutics Chairman Buys 105,824 Shares, Raises Stake to 21.95%

CytoMed Therapeutics’ Chairman Increases Effective Holdings to 21.95%

CytoMed Therapeutics Submits Cash Bid to Acquire TC BioPharm Assets

CytoMed Therapeutics Announces Promising Preclinical Results for Allogeneic γδ T Cell Therapy in Acute Myeloid Leukemia, Plans Clinical Trials in Southeast Asia

CytoMed Therapeutics Ltd expected to post a loss of 3 cents a share - Earnings Preview

CytoMed Therapeutics Ltd. Expands into Auto-Immune Disease Treatments Following Strategic Cord Blood Bank Acquisition

CytoMed Therapeutics Limited Announces At-the-Market (ATM) Offering Program

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/GDTC/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"GDTC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GDTC\",,,,,undefined,":{"symbol":"GDTC","market":"US","secType":"STK","nameCN":"CytoMed Therapeutics Limited","latestPrice":1.08,"timestamp":1770325200000,"preClose":0.8499,"halted":0,"volume":21991072,"hourTrading":{"tag":"盘后","latestPrice":1.1099,"preClose":1.08,"latestTime":"19:09 EST","volume":224435,"amount":245469.901053,"timestamp":1770336551123,"change":0.0299,"changeRate":0.027685,"amplitude":0.12963},"delay":0,"changeRate":0.2707377338510414,"floatShares":5988082,"shares":11733699,"eps":-0.249893,"marketStatus":"Post-Mkt","change":0.2301,"latestTime":"02-05 19:09:57 EST","open":1.035,"high":1.25,"low":0.9012,"amount":25023150.4278944,"amplitude":0.410401,"askPrice":1.11,"askSize":100,"bidPrice":1.08,"bidSize":14446,"shortable":3,"etf":0,"ttmEps":-0.249893,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1770339600000},"marketStatusCode":4,"adr":0,"listingDate":1681444800000,"exchange":"NASDAQ","adjPreClose":0.8499,"preHourTrading":{"tag":"盘前","latestPrice":1.0398,"preClose":0.8304,"latestTime":"09:29 EST","volume":4501883,"amount":5135250.218140201,"timestamp":1770301798740,"change":0.2094,"changeRate":0.252168,"amplitude":0.445568},"postHourTrading":{"tag":"盘后","latestPrice":1.1099,"preClose":1.08,"latestTime":"19:09 EST","volume":224435,"amount":245469.901053,"timestamp":1770336551123,"change":0.0299,"changeRate":0.027685,"amplitude":0.12963},"volumeRatio":10.709307},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GDTC\",,,,,undefined,":{"symbol":"GDTC","floatShares":5988082,"roa":"-22.85%","roe":"-42.33%","lyrEps":-0.1598,"volumeRatio":10.709307,"shares":11733699,"dividePrice":0,"high":1.25,"amplitude":0.410401,"preClose":0.8499,"low":0.9012,"week52Low":0.7282,"pbRate":"2.26","psRate":"22.15","week52High":3.68,"institutionHeld":0,"latestPrice":1.08,"committee":0.986251,"eps":-0.249893,"divideRate":0,"volume":21991072,"delay":0,"ttmEps":-0.249893,"open":1.035,"prevYearClose":1.335,"prevWeekClose":0.8066,"prevMonthClose":0.8066,"prevQuarterClose":1.335,"fiveDayClose":0.8413,"twentyDayClose":1.39,"sixtyDayClose":1.88},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/GDTC\",params:#limit:5,,,undefined,":[{"date":"2025-09-30","symbol":"GDTC","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1759219200000,"name":null,"time":"Pre-Market","dateTimestamp":1759204800000,"actualEps":null},{"market":"US","date":"2025-04-28","symbol":"GDTC","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1745812800000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2024-10-08","symbol":"GDTC","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1728360000000,"reportTimeType":"pre","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"GDTC\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"GDTC\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/GDTC\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"GDTC","date":"2026-02-04","current":-4.60197,"percent":0.994083,"low":-32.187359,"twenty":-15.04783,"median":-11.911423,"eighty":-7.707296,"high":-3.224953,"avg":-11.968649,"sd":4.573953,"marketCap":9809000},"quantilePoints":[{"date":"2023-04-14","current":-32.187359,"twenty":-32.187359,"median":-32.187359,"eighty":-32.187359,"marketCap":49229185},{"date":"2023-04-21","current":-23.996859,"twenty":-28.890857,"median":-26.696093,"eighty":-25.221924,"marketCap":36429597},{"date":"2023-04-28","current":-25.0053,"twenty":-27.115492,"median":-25.0053,"eighty":-23.900672,"marketCap":37847397},{"date":"2023-05-05","current":-17.068346,"twenty":-26.444454,"median":-24.364194,"eighty":-23.760246,"marketCap":40232278},{"date":"2023-05-12","current":-13.070634,"twenty":-25.432878,"median":-23.948766,"eighty":-17.250936,"marketCap":30740891},{"date":"2023-05-19","current":-13.942715,"twenty":-25.048625,"median":-23.457114,"eighty":-14.326746,"marketCap":32381864},{"date":"2023-05-26","current":-13.013489,"twenty":-24.831622,"median":-17.395,"eighty":-13.746669,"marketCap":30084502},{"date":"2023-06-02","current":-13.452888,"twenty":-24.533797,"median":-16.759279,"eighty":-13.607683,"marketCap":31244478},{"date":"2023-06-07","current":-13.846324,"twenty":-24.335541,"median":-14.413802,"eighty":-13.619509,"marketCap":32166825},{"date":"2023-06-16","current":-13.983516,"twenty":-24.176114,"median":-14.413777,"eighty":-13.645416,"marketCap":32743291},{"date":"2023-06-23","current":-14.403184,"twenty":-23.996859,"median":-14.329877,"eighty":-13.648316,"marketCap":33550344},{"date":"2023-06-30","current":-15.414863,"twenty":-23.919909,"median":-14.329877,"eighty":-13.682012,"marketCap":35626776},{"date":"2023-07-07","current":-16.268645,"twenty":-23.861886,"median":-14.413777,"eighty":-13.732611,"marketCap":37585609},{"date":"2023-07-14","current":-21.482937,"twenty":-23.861886,"median":-15.213534,"eighty":-13.784206,"marketCap":50844336},{"date":"2023-07-21","current":-18.816327,"twenty":-23.60868,"median":-15.364674,"eighty":-13.827738,"marketCap":44387912},{"date":"2023-07-28","current":-19.927212,"twenty":-22.272608,"median":-15.785661,"eighty":-13.849589,"marketCap":46924364},{"date":"2023-08-04","current":-20.727324,"twenty":-21.444799,"median":-16.359428,"eighty":-13.855946,"marketCap":48423177},{"date":"2023-08-11","current":-20.483755,"twenty":-21.444799,"median":-17.251819,"eighty":-13.870774,"marketCap":47616124},{"date":"2023-08-18","current":-19.114176,"twenty":-21.359469,"median":-17.475439,"eighty":-13.917149,"marketCap":44042032},{"date":"2023-08-25","current":-16.863134,"twenty":-21.233742,"median":-17.849445,"eighty":-13.94778,"marketCap":38969128},{"date":"2023-09-01","current":-16.79246,"twenty":-21.145427,"median":-17.441381,"eighty":-13.967696,"marketCap":38917246},{"date":"2023-09-08","current":-17.041842,"twenty":-21.112661,"median":-17.432432,"eighty":-13.98064,"marketCap":39084421},{"date":"2023-09-15","current":-18.059224,"twenty":-21.060627,"median":-17.448514,"eighty":-14.024429,"marketCap":41505580},{"date":"2023-09-22","current":-18.116195,"twenty":-20.905866,"median":-17.493416,"eighty":-14.200663,"marketCap":41506733},{"date":"2023-09-29","current":-17.671976,"twenty":-20.821633,"median":-17.637629,"eighty":-14.251467,"marketCap":40467941},{"date":"2023-10-06","current":-18.352226,"twenty":-20.772997,"median":-17.686193,"eighty":-14.254026,"marketCap":41966753},{"date":"2023-10-13","current":-17.809938,"twenty":-20.67861,"median":-17.679085,"eighty":-14.285893,"marketCap":40738880},{"date":"2023-10-20","current":-16.930791,"twenty":-20.479432,"median":-17.671976,"eighty":-14.405298,"marketCap":38622095},{"date":"2023-10-27","current":-17.724189,"twenty":-20.470787,"median":-17.686193,"eighty":-14.409525,"marketCap":40467941},{"date":"2023-11-03","current":-19.557394,"twenty":-20.426928,"median":-17.699338,"eighty":-14.413782,"marketCap":44849085},{"date":"2023-11-10","current":-19.779409,"twenty":-20.426928,"median":-17.758237,"eighty":-14.577325,"marketCap":45656138},{"date":"2023-11-17","current":-20.199358,"twenty":-20.400538,"median":-17.829691,"eighty":-15.002657,"marketCap":46924364},{"date":"2023-11-24","current":-13.288871,"twenty":-20.365537,"median":-17.770523,"eighty":-14.407411,"marketCap":42543220},{"date":"2023-12-01","current":-13.234082,"twenty":-20.295603,"median":-17.712483,"eighty":-14.213244,"marketCap":42543220},{"date":"2023-12-08","current":-12.420365,"twenty":-20.261217,"median":-17.662803,"eighty":-13.946092,"marketCap":39826910},{"date":"2023-12-15","current":-11.641369,"twenty":-20.239107,"median":-17.621628,"eighty":-13.848501,"marketCap":37700902},{"date":"2023-12-22","current":-15.355974,"twenty":-20.208527,"median":-17.491329,"eighty":-13.818445,"marketCap":49691403},{"date":"2023-12-29","current":-18.408812,"twenty":-20.199358,"median":-17.49058,"eighty":-13.846324,"marketCap":59952505},{"date":"2024-01-05","current":-15.523017,"twenty":-20.173796,"median":-17.483753,"eighty":-13.849589,"marketCap":50152576},{"date":"2024-01-12","current":-15.504777,"twenty":-20.143787,"median":-17.439566,"eighty":-13.855946,"marketCap":49921990},{"date":"2024-01-19","current":-13.786478,"twenty":-20.098931,"median":-17.372527,"eighty":-13.854553,"marketCap":44042032},{"date":"2024-01-26","current":-13.753965,"twenty":-19.997652,"median":-17.329203,"eighty":-13.854553,"marketCap":44042032},{"date":"2024-02-02","current":-12.568738,"twenty":-19.916959,"median":-17.192655,"eighty":-13.771027,"marketCap":40351495},{"date":"2024-02-09","current":-8.105087,"twenty":-19.852711,"median":-17.147281,"eighty":-13.646141,"marketCap":25825694},{"date":"2024-02-16","current":-9.076446,"twenty":-19.753496,"median":-17.068346,"eighty":-13.40372,"marketCap":28938613},{"date":"2024-02-23","current":-8.044355,"twenty":-19.710912,"median":-17.041842,"eighty":-13.347563,"marketCap":25710401},{"date":"2024-03-01","current":-7.261373,"twenty":-19.668319,"median":-16.896963,"eighty":-13.264875,"marketCap":23173949},{"date":"2024-03-08","current":-7.340929,"twenty":-19.557394,"median":-16.450211,"eighty":-13.126445,"marketCap":23635122},{"date":"2024-03-15","current":-7.674245,"twenty":-19.513851,"median":-16.233519,"eighty":-13.055436,"marketCap":24672761},{"date":"2024-03-22","current":-8.225396,"twenty":-19.294578,"median":-15.795176,"eighty":-12.699525,"marketCap":26286867},{"date":"2024-03-28","current":-8.115312,"twenty":-19.114176,"median":-15.75403,"eighty":-12.579008,"marketCap":25825694},{"date":"2024-04-05","current":-7.410887,"twenty":-19.082247,"median":-15.513897,"eighty":-12.420365,"marketCap":23635122},{"date":"2024-04-12","current":-7.65753,"twenty":-18.941307,"median":-15.414863,"eighty":-11.641369,"marketCap":24269235},{"date":"2024-04-19","current":-7.636297,"twenty":-18.852191,"median":-15.302207,"eighty":-9.130689,"marketCap":24096295},{"date":"2024-04-26","current":-8.357058,"twenty":-18.838972,"median":-15.213534,"eighty":-8.980148,"marketCap":25388000},{"date":"2024-05-03","current":-7.962415,"twenty":-18.827004,"median":-15.042386,"eighty":-8.543858,"marketCap":24234000},{"date":"2024-05-10","current":-8.019464,"twenty":-18.816327,"median":-14.686341,"eighty":-8.394768,"marketCap":24487880},{"date":"2024-05-17","current":-8.003724,"twenty":-18.67885,"median":-14.413777,"eighty":-8.168989,"marketCap":24580200},{"date":"2024-05-24","current":-7.621351,"twenty":-18.609148,"median":-14.274039,"eighty":-8.138739,"marketCap":23310800},{"date":"2024-05-31","current":-7.573126,"twenty":-18.591233,"median":-14.25339,"eighty":-8.112764,"marketCap":23195400},{"date":"2024-06-07","current":-7.781706,"twenty":-18.580215,"median":-14.149686,"eighty":-8.062992,"marketCap":23886646},{"date":"2024-06-14","current":-7.763239,"twenty":-18.476719,"median":-14.065397,"eighty":-8.040579,"marketCap":23772400},{"date":"2024-06-21","current":-7.258799,"twenty":-18.395516,"median":-13.981119,"eighty":-8.003519,"marketCap":22156800},{"date":"2024-06-28","current":-7.70107,"twenty":-18.382221,"median":-13.96648,"eighty":-7.975269,"marketCap":23430816},{"date":"2024-07-05","current":-7.696127,"twenty":-18.361565,"median":-13.946936,"eighty":-7.947287,"marketCap":23541600},{"date":"2024-07-12","current":-7.684396,"twenty":-18.314998,"median":-13.858733,"eighty":-7.939183,"marketCap":23657000},{"date":"2024-07-15","current":-7.608577,"twenty":-18.302589,"median":-13.855249,"eighty":-7.925519,"marketCap":23426200},{"date":"2024-08-02","current":-6.534197,"twenty":-18.29018,"median":-13.851766,"eighty":-7.898651,"marketCap":20195000},{"date":"2024-08-09","current":-6.59149,"twenty":-18.236861,"median":-13.793169,"eighty":-7.838233,"marketCap":20541200},{"date":"2024-08-16","current":-6.378946,"twenty":-18.219132,"median":-13.753965,"eighty":-7.780156,"marketCap":19964200},{"date":"2024-08-23","current":-5.853677,"twenty":-18.134107,"median":-13.646503,"eighty":-7.759668,"marketCap":18464000},{"date":"2024-08-30","current":-5.279227,"twenty":-18.116195,"median":-13.552172,"eighty":-7.70107,"marketCap":16733000},{"date":"2024-09-06","current":-5.41733,"twenty":-18.115793,"median":-13.370941,"eighty":-7.683775,"marketCap":17194600},{"date":"2024-09-13","current":-5.428022,"twenty":-18.095282,"median":-13.351778,"eighty":-7.658912,"marketCap":17194600},{"date":"2024-09-20","current":-5.595314,"twenty":-18.088626,"median":-13.288871,"eighty":-7.633823,"marketCap":17887000},{"date":"2024-09-27","current":-5.304149,"twenty":-18.065027,"median":-13.255069,"eighty":-7.6083,"marketCap":17079200},{"date":"2024-10-04","current":-8.621532,"twenty":-17.980434,"median":-13.209908,"eighty":-7.604577,"marketCap":20353098},{"date":"2024-10-11","current":-9.901703,"twenty":-17.910917,"median":-13.087276,"eighty":-7.6083,"marketCap":23195400},{"date":"2024-10-18","current":-10.541651,"twenty":-17.892717,"median":-13.052108,"eighty":-7.615004,"marketCap":24581354},{"date":"2024-10-25","current":-15.069135,"twenty":-17.857812,"median":-13.032799,"eighty":-7.620403,"marketCap":34966200},{"date":"2024-10-31","current":-11.088307,"twenty":-17.825741,"median":-12.896116,"eighty":-7.625215,"marketCap":25683424},{"date":"2024-11-08","current":-12.649628,"twenty":-17.793661,"median":-12.776012,"eighty":-7.632315,"marketCap":29311600},{"date":"2024-11-15","current":-10.716333,"twenty":-17.768066,"median":-12.687238,"eighty":-7.635911,"marketCap":24464800},{"date":"2024-11-22","current":-11.15139,"twenty":-17.737808,"median":-12.650128,"eighty":-7.643199,"marketCap":25388000},{"date":"2024-11-29","current":-11.887986,"twenty":-17.719507,"median":-12.579008,"eighty":-7.651693,"marketCap":27119000},{"date":"2024-12-06","current":-14.681291,"twenty":-17.701967,"median":-12.573873,"eighty":-7.658221,"marketCap":33581400},{"date":"2024-12-13","current":-13.732197,"twenty":-17.680506,"median":-12.650128,"eighty":-7.66504,"marketCap":31273400},{"date":"2024-12-20","current":-12.503123,"twenty":-17.664638,"median":-12.653754,"eighty":-7.673925,"marketCap":28157600},{"date":"2024-12-27","current":-14.317736,"twenty":-17.651044,"median":-12.687238,"eighty":-7.675654,"marketCap":32276226},{"date":"2025-01-03","current":-18.055457,"twenty":-17.65363,"median":-12.744378,"eighty":-7.681291,"marketCap":40390000},{"date":"2025-01-10","current":-11.811271,"twenty":-17.657299,"median":-12.777378,"eighty":-7.683775,"marketCap":26426600},{"date":"2025-01-17","current":-12.301565,"twenty":-17.643286,"median":-12.712745,"eighty":-7.687173,"marketCap":27580600},{"date":"2025-01-24","current":-12.618326,"twenty":-17.632572,"median":-12.69622,"eighty":-7.692823,"marketCap":28503800},{"date":"2025-01-31","current":-13.164329,"twenty":-17.623838,"median":-12.704483,"eighty":-7.699093,"marketCap":29888600},{"date":"2025-02-07","current":-14.353547,"twenty":-17.572403,"median":-12.778743,"eighty":-7.704188,"marketCap":32542800},{"date":"2025-02-14","current":-12.677025,"twenty":-17.530008,"median":-12.98759,"eighty":-7.733689,"marketCap":28850000},{"date":"2025-02-21","current":-13.835636,"twenty":-17.51154,"median":-13.012667,"eighty":-7.754009,"marketCap":31735000},{"date":"2025-02-28","current":-14.210189,"twenty":-17.492282,"median":-13.052108,"eighty":-7.758106,"marketCap":32312000},{"date":"2025-03-07","current":-13.937974,"twenty":-17.490045,"median":-13.082373,"eighty":-7.761096,"marketCap":32081200},{"date":"2025-03-14","current":-13.430529,"twenty":-17.48485,"median":-13.094112,"eighty":-7.766851,"marketCap":30811800},{"date":"2025-03-21","current":-13.383835,"twenty":-17.469943,"median":-13.100143,"eighty":-7.774553,"marketCap":30696400},{"date":"2025-03-28","current":-11.347106,"twenty":-17.450304,"median":-13.096368,"eighty":-7.778849,"marketCap":25965000},{"date":"2025-04-04","current":-12.036679,"twenty":-17.433859,"median":-13.074526,"eighty":-7.780776,"marketCap":27638300},{"date":"2025-04-11","current":-12.537352,"twenty":-17.40419,"median":-13.068746,"eighty":-7.789167,"marketCap":28850000},{"date":"2025-04-17","current":-11.507236,"twenty":-17.370437,"median":-13.052108,"eighty":-7.801638,"marketCap":26888200},{"date":"2025-04-25","current":-11.618406,"twenty":-17.362024,"median":-13.012667,"eighty":-7.813051,"marketCap":27119000},{"date":"2025-05-02","current":-13.832921,"twenty":-17.348774,"median":-13.013489,"eighty":-7.845017,"marketCap":26542000},{"date":"2025-05-09","current":-13.68949,"twenty":-17.287631,"median":-13.057676,"eighty":-7.87455,"marketCap":26542000},{"date":"2025-05-16","current":-13.868797,"twenty":-17.239986,"median":-13.070634,"eighty":-7.884698,"marketCap":26888200},{"date":"2025-05-23","current":-13.322458,"twenty":-17.187034,"median":-13.074526,"eighty":-7.889275,"marketCap":25965000},{"date":"2025-05-30","current":-13.687893,"twenty":-17.16455,"median":-13.086265,"eighty":-7.898651,"marketCap":26772800},{"date":"2025-06-06","current":-11.908459,"twenty":-17.160716,"median":-13.078418,"eighty":-7.932236,"marketCap":23310800},{"date":"2025-06-13","current":-12.526503,"twenty":-17.133847,"median":-13.065995,"eighty":-7.943814,"marketCap":24637900},{"date":"2025-06-20","current":-13.772748,"twenty":-17.086739,"median":-13.057676,"eighty":-7.948445,"marketCap":26888200},{"date":"2025-06-27","current":-13.442284,"twenty":-17.069669,"median":-13.068746,"eighty":-7.959853,"marketCap":26542000},{"date":"2025-07-03","current":-12.84526,"twenty":-17.062326,"median":-13.068746,"eighty":-7.969734,"marketCap":25369536},{"date":"2025-07-11","current":-12.919472,"twenty":-17.04843,"median":-13.065995,"eighty":-7.975105,"marketCap":25388000},{"date":"2025-07-18","current":-11.970391,"twenty":-17.036468,"median":-13.047615,"eighty":-7.978113,"marketCap":23426200},{"date":"2025-07-25","current":-11.1234,"twenty":-16.971629,"median":-13.019911,"eighty":-7.991875,"marketCap":21926000},{"date":"2025-08-01","current":-11.187429,"twenty":-16.890197,"median":-12.997048,"eighty":-8.001973,"marketCap":21695200},{"date":"2025-08-08","current":-10.961291,"twenty":-16.82073,"median":-12.950122,"eighty":-8.003587,"marketCap":21464400},{"date":"2025-08-15","current":-10.507317,"twenty":-16.587111,"median":-12.881751,"eighty":-8.010941,"marketCap":20587360},{"date":"2025-08-22","current":-10.51661,"twenty":-16.341271,"median":-12.777378,"eighty":-8.01798,"marketCap":20541200},{"date":"2025-08-29","current":-11.76616,"twenty":-16.252726,"median":-12.726567,"eighty":-8.028735,"marketCap":23080000},{"date":"2025-09-05","current":-11.240492,"twenty":-16.235238,"median":-12.69622,"eighty":-8.038691,"marketCap":21926000},{"date":"2025-09-12","current":-11.811257,"twenty":-16.218885,"median":-12.674689,"eighty":-8.045093,"marketCap":23195400},{"date":"2025-09-19","current":-11.053208,"twenty":-16.143284,"median":-12.664496,"eighty":-8.048004,"marketCap":21695200},{"date":"2025-09-26","current":-11.68813,"twenty":-15.944154,"median":-12.649878,"eighty":-8.054123,"marketCap":22733800},{"date":"2025-10-03","current":-8.151484,"twenty":-15.79137,"median":-12.618326,"eighty":-8.058905,"marketCap":23195400},{"date":"2025-10-10","current":-9.191333,"twenty":-15.773009,"median":-12.573873,"eighty":-8.061972,"marketCap":25965000},{"date":"2025-10-17","current":-9.15018,"twenty":-15.7494,"median":-12.537352,"eighty":-8.061972,"marketCap":25965000},{"date":"2025-10-24","current":-9.919614,"twenty":-15.718039,"median":-12.519457,"eighty":-8.081673,"marketCap":28042200},{"date":"2025-10-31","current":-8.788032,"twenty":-15.618055,"median":-12.473628,"eighty":-8.106053,"marketCap":24811000},{"date":"2025-11-07","current":-8.367389,"twenty":-15.515721,"median":-12.427329,"eighty":-8.110133,"marketCap":23541600},{"date":"2025-11-14","current":-7.839227,"twenty":-15.484129,"median":-12.317266,"eighty":-8.058905,"marketCap":22156800},{"date":"2025-11-21","current":-7.393794,"twenty":-15.43784,"median":-12.304305,"eighty":-8.051614,"marketCap":20772000},{"date":"2025-11-28","current":-7.499871,"twenty":-15.403085,"median":-12.290011,"eighty":-8.036803,"marketCap":21233600},{"date":"2025-12-05","current":-7.530923,"twenty":-15.347676,"median":-12.246344,"eighty":-8.00613,"marketCap":21349000},{"date":"2025-12-12","current":-6.777454,"twenty":-15.309573,"median":-12.141625,"eighty":-7.976326,"marketCap":19271800},{"date":"2025-12-19","current":-6.320053,"twenty":-15.285071,"median":-12.121967,"eighty":-7.952165,"marketCap":18002400},{"date":"2025-12-26","current":-6.211198,"twenty":-15.265632,"median":-12.113423,"eighty":-7.898651,"marketCap":17771600},{"date":"2026-01-02","current":-5.395333,"twenty":-15.224986,"median":-12.083343,"eighty":-7.882532,"marketCap":15405900},{"date":"2026-01-09","current":-5.291457,"twenty":-15.213792,"median":-12.061574,"eighty":-7.833207,"marketCap":15117400},{"date":"2026-01-16","current":-3.764422,"twenty":-15.190549,"median":-12.044113,"eighty":-7.781396,"marketCap":10732200},{"date":"2026-01-23","current":-3.826015,"twenty":-15.147218,"median":-11.990216,"eighty":-7.768658,"marketCap":10964154},{"date":"2026-01-30","current":-3.347404,"twenty":-15.090345,"median":-11.944017,"eighty":-7.748526,"marketCap":9708602},{"date":"2026-02-04","current":-3.399704,"twenty":-15.04783,"median":-11.911423,"eighty":-7.707296,"marketCap":9809000}],"updateTime":1770325056562},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"GDTC\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2606710757","title":"CytoMed Therapeutics Refutes Misleading Claims and Reaffirms Clinical Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2606710757","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606710757?lang=en_us&edition=fundamental","pubTime":"2026-01-28 23:00","pubTimestamp":1769612417,"startTime":"0","endTime":"0","summary":"CytoMed Therapeutics Ltd. has issued a statement refuting recent inaccurate and misleading claims about its research programs, clinical progress, and operations. The company clarified that its scientific focus, development status, and regulatory standing have been mischaracterized by certain public statements. CytoMed emphasized that its lead CAR γδ T cell therapy has regulatory approval for a first-in-human clinical trial currently underway at National University Hospital in Singapore, conducted under appropriate regulatory and ethical guidelines. The company also noted that other programs, such as iPSC-derived γδ NKT cell therapies, remain in preclinical development and are not approved for commercial use. CytoMed reaffirmed its commitment to accurate communication and compliance with applicable regulations, and reserved the right to address the spread of false or misleading information.Disclaimer: This news brief was created by Public Technologies  using generative artificial intell","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260128:nNDLM0dWy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4112","LU0314104364.USD","LU2210149790.SGD","SG9999014005.SGD","IE00B64PRP62.GBP","SG9999014021.USD","SG9999014013.SGD","BK4585","SG9999014039.USD","LU2210150020.SGD","NDAQ","BK4588","IE00B3QW5Z07.USD","LU2095319765.USD","IE00BKPKM429.USD","IE00BGHQF748.EUR","GDTC"],"gpt_icon":0},{"id":"2603684471","title":"Cytomed sees ‘enough resources’ to continue activites for ‘at least a year’","url":"https://stock-news.laohu8.com/highlight/detail?id=2603684471","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603684471?lang=en_us&edition=fundamental","pubTime":"2026-01-13 21:17","pubTimestamp":1768310244,"startTime":"0","endTime":"0","summary":"CytoMed Therapeutics (GDTC) updates shareholders as the company enters a new year in 2026. The company said, “As mentioned in previous announcement...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cytomed-sees-enough-resources-to-continue-activites-for-at-least-a-year-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cytomed-sees-enough-resources-to-continue-activites-for-at-least-a-year-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GDTC","BK4139"],"gpt_icon":0},{"id":"2603668108","title":"Cytomed Therapeutics Reports Sufficient Funding and Advances Clinical Trials for Cancer Therapies","url":"https://stock-news.laohu8.com/highlight/detail?id=2603668108","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603668108?lang=en_us&edition=fundamental","pubTime":"2026-01-13 21:01","pubTimestamp":1768309268,"startTime":"0","endTime":"0","summary":"CytoMed Therapeutics Ltd., a Singapore-based clinical stage biopharmaceutical company, announced that it has sufficient resources to fund its activities for at least the next year, supported by its low-cost infrastructure in Southeast Asia. The company is exploring additional funding options including licensing, asset monetisation from real estate properties, and long-term strategic partnerships with biotechs and hospitals. CytoMed’s Chairman, Peter Choo, intends to increase his shareholding in the company and will make a formal announcement accordingly. CytoMed has diversified its product pipeline through its new subsidiary, LongevityBank, by developing clinical-grade cord blood-derived Natural Killer  cells, with support from Enterprise Singapore. The company is also advancing clinical trials for its allogeneic unmodified Gamma Delta (γδ) T cells  in collaboration with Universiti Malaya, targeting a first-in-human Phase I trial for no-option cancer patients in Malaysia, with plans to","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260113:nNDLc6DKPq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","BK4585","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","LU0314104364.USD","LU2095319765.USD","BK4588","SG9999014021.USD","SG9999014039.USD","BK4112","NDAQ","SG9999014005.SGD","IE00B64PRP62.GBP","BK4139","IE00BKPKM429.USD","SG9999014013.SGD","GDTC","LU2210149790.SGD"],"gpt_icon":0},{"id":"2603668433","title":"CytoMed Therapeutics’ new year update and seeks shareholders’ feedback on proposal to improve shareholder value for their patient capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2603668433","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603668433?lang=en_us&edition=fundamental","pubTime":"2026-01-13 21:00","pubTimestamp":1768309200,"startTime":"0","endTime":"0","summary":"SINGAPORE, Jan.  13, 2026  (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or the “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessin","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/13/3217726/0/en/CytoMed-Therapeutics-new-year-update-and-seeks-shareholders-feedback-on-proposal-to-improve-shareholder-value-for-their-patient-capital.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","BK4007","BK4539","GDTC","BK4139"],"gpt_icon":0},{"id":"2589335353","title":"CytoMed Therapeutics Partners with Universiti Malaya Medical Centre for First-In-Human Gamma Delta T Cell Cancer Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2589335353","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589335353?lang=en_us&edition=fundamental","pubTime":"2025-12-08 21:00","pubTimestamp":1765198857,"startTime":"0","endTime":"0","summary":"CytoMed Therapeutics Ltd., a Singapore-based clinical stage biopharmaceutical company, has entered into a Memorandum of Understanding with Universiti Malaya Medical Centre  to establish a multi-site, first-in-human Phase I clinical trial in Malaysia. The collaboration aims to investigate the safety and efficacy of CytoMed's patented allogeneic unmodified Gamma Delta (γδ) T cells  for no-option cancer patients. This partnership will advance affordable, off-the-shelf donor-derived cell-based immunotherapies, potentially offering new treatment alternatives for patients with limited options.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cytomed Therapeutics Ltd. published the original content used to generate this news brief via GlobeNews","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nNDL9f3Jcm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","LU2210150020.SGD","IE00B64PRP62.GBP","IE00BGHQF748.EUR","SG9999014039.USD","NDAQ","BK4139","LU2095319765.USD","BK4585","BK4588","LU2210149790.SGD","BK4112","SG9999014013.SGD","SG9999014005.SGD","SG9999014021.USD","GDTC","IE00BKPKM429.USD","IE00B3QW5Z07.USD"],"gpt_icon":0},{"id":"2584955235","title":"CytoMed completes acquisition of T cell technology of TC BioPharm","url":"https://stock-news.laohu8.com/highlight/detail?id=2584955235","media":"TIPRANKS","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584955235?lang=en_us&edition=fundamental","pubTime":"2025-11-18 22:37","pubTimestamp":1763476632,"startTime":"0","endTime":"0","summary":"CytoMed Therapeutics (GDTC) announced that it has completed with full payment the acquisition of the allogeneic gamma delta T cell technology of TC...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cytomed-completes-acquisition-of-t-cell-technology-of-tc-biopharm-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cytomed-completes-acquisition-of-t-cell-technology-of-tc-biopharm-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GDTC","BK4009","TCBP","BK4139","TC"],"gpt_icon":0},{"id":"2584937473","title":"Press Release: CytoMed Therapeutics Completes Acquisition of T Cell Technology from UK to Treat Cancers in China and India","url":"https://stock-news.laohu8.com/highlight/detail?id=2584937473","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584937473?lang=en_us&edition=fundamental","pubTime":"2025-11-18 21:00","pubTimestamp":1763470800,"startTime":"0","endTime":"0","summary":"SINGAPORE, Nov. 18, 2025  -- CytoMed Therapeutics Limited  , a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary novel technologies to develop affordable donor-derived cell-based immunotherapies for the treatment of a broad range of cancers, including both blood and solid tumours, announced today that it has completed with full payment the acquisition of the allogeneic gamma delta T cell technology  of TC BioPharm Limited , a subsidiary of TC BioPharm  PLC . This follows CytoMed's announcement on October 14, 2025 regarding its proposed acquisition of potentially synergistic assets from TCBL.\"State Council Decree No. 818 released on October 10, 2025 establishes a definitive regulatory pathway from clinical research to reimbursable clinical application for cell therapies in China. The key distinction is that these therapies are to be regulated as biotechnological medical procedures under a 'clinical study to clinical application' pathway withi","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GDTC","BK4539","BK4139","MNDmain","LENZ","BK4007"],"gpt_icon":0},{"id":"2581093657","title":"CytoMed Therapeutics Secures $500,000 Investment for LongevityBank Subsidiary","url":"https://stock-news.laohu8.com/highlight/detail?id=2581093657","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581093657?lang=en_us&edition=fundamental","pubTime":"2025-11-06 21:02","pubTimestamp":1762434125,"startTime":"0","endTime":"0","summary":"CytoMed Therapeutics Ltd. has secured a non-dilutive investment for its subsidiary LongevityBank Pte Ltd from ICH Capital Pte Ltd. ICH Capital will invest up to US$500,000 for a 10% post-money stake in LongevityBank. LongevityBank focuses on autologous therapies and personalized cellular banking services, while CytoMed continues to develop donor-derived allogeneic therapies.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cytomed Therapeutics Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 06, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nNDLTMR2w:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GDTC","BK4139"],"gpt_icon":0},{"id":"2581093372","title":"CytoMed Therapeutics Granted Patent for Gamma Delta T Cell Technology by China National Intellectual Property Administration","url":"https://stock-news.laohu8.com/highlight/detail?id=2581093372","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581093372?lang=en_us&edition=fundamental","pubTime":"2025-11-06 21:01","pubTimestamp":1762434096,"startTime":"0","endTime":"0","summary":"CytoMed Therapeutics Ltd. has been granted a patent by the China National Intellectual Property Administration  for its proprietary gamma delta T cell technology and the associated chimeric antigen receptor gamma delta T cell  technology.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cytomed Therapeutics Ltd. published the original content used to generate this news brief via GlobeNewswire  on November 06, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nNDL4Nx7dW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","IE00B3QW5Z07.USD","LU2210149790.SGD","IE00B64PRP62.GBP","IE00BGHQF748.EUR","LU0314104364.USD","BK4588","NDAQ","LU2095319765.USD","IE00BKPKM429.USD","GDTC","BK4585","BK4139","LU2210150020.SGD"],"gpt_icon":0},{"id":"2581093986","title":"Press Release: CytoMed Therapeutics Secures Non-Dilutive Investment for Subsidiary LongevityBank from ICH Capital and Updates on New China Strategy","url":"https://stock-news.laohu8.com/highlight/detail?id=2581093986","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581093986?lang=en_us&edition=fundamental","pubTime":"2025-11-06 21:00","pubTimestamp":1762434000,"startTime":"0","endTime":"0","summary":"SINGAPORE, Nov. 06, 2025  -- CytoMed Therapeutics Limited  , a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel affordable donor-derived cell-based immunotherapies for the treatment of a broad range of cancers, including both blood and solid tumours, announced today that it secures non-dilutive investment for its subsidiary, LongevityBank Pte Ltd  from ICH Capital Pte Ltd .China's State Council Decree No. 818 released on October 10, 2025 establishes a definitive regulatory pathway from clinical research to reimbursable clinical application for cell therapies. The key distinction is that these therapies are to be regulated as biotechnological medical procedures under a 'clinical study to clinical ap","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","BK4139","BK4539","BK4007","GDTC"],"gpt_icon":0},{"id":"2577369092","title":"CytoMed Therapeutics Chairman Buys 105,824 Shares, Raises Stake to 21.95%","url":"https://stock-news.laohu8.com/highlight/detail?id=2577369092","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577369092?lang=en_us&edition=fundamental","pubTime":"2025-10-22 20:01","pubTimestamp":1761134505,"startTime":"0","endTime":"0","summary":"CytoMed Therapeutics Ltd. announced that its Executive Chairman, Peter Choo, increased his effective holdings in the company to 21.95% through recent open-market purchases of 105,824 shares. With these transactions and his existing personal stake of 187,500 shares, along with indirect holdings through Glorious Finance Limited and EP Capital Inc, Choo now owns a total of 2,388,246 shares. The price per share was not disclosed.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cytomed Therapeutics Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on October 22, 2025, and is solely responsible ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251022:nNDL6PQ2Sz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GDTC"],"gpt_icon":0},{"id":"2577361980","title":"CytoMed Therapeutics’ Chairman Increases Effective Holdings to 21.95%","url":"https://stock-news.laohu8.com/highlight/detail?id=2577361980","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577361980?lang=en_us&edition=fundamental","pubTime":"2025-10-22 20:00","pubTimestamp":1761134400,"startTime":"0","endTime":"0","summary":"SINGAPORE, Oct.  22, 2025  (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing it","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/22/3171038/0/en/CytoMed-Therapeutics-Chairman-Increases-Effective-Holdings-to-21-95.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","BK4007","BK4539","GDTC","BK4139"],"gpt_icon":0},{"id":"2575974032","title":"CytoMed Therapeutics Submits Cash Bid to Acquire TC BioPharm Assets","url":"https://stock-news.laohu8.com/highlight/detail?id=2575974032","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575974032?lang=en_us&edition=fundamental","pubTime":"2025-10-14 20:00","pubTimestamp":1760443225,"startTime":"0","endTime":"0","summary":"CytoMed Therapeutics Limited has submitted a cash bid to acquire selected assets of TC BioPharm Limited, following the appointment of joint administrators to TC BioPharm earlier this month. Both companies focus on developing donor-derived allogeneic gamma delta T cell therapies for cancer treatment. CytoMed recently completed an acquisition of a licensed cord blood bank in Malaysia and aims to leverage these assets to accelerate its development of affordable cell-based immunotherapies for cancer and autoimmune diseases. The company believes the addition of TC BioPharm's assets will strengthen its expertise in allogeneic cell therapies and support its mission to provide new therapeutic options for patients with unmet medical needs.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251014:nNDL8LmbRv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","IE00BKPKM429.USD","TCBPY","BK4585","LU2210149790.SGD","LU2095319765.USD","BK4139","BK4588","GDTC","LU2210150020.SGD","BK4112","LU0314104364.USD","IE00B64PRP62.GBP","IE00BGHQF748.EUR","NDAQ"],"gpt_icon":0},{"id":"2572519573","title":"CytoMed Therapeutics Announces Promising Preclinical Results for Allogeneic γδ T Cell Therapy in Acute Myeloid Leukemia, Plans Clinical Trials in Southeast Asia","url":"https://stock-news.laohu8.com/highlight/detail?id=2572519573","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572519573?lang=en_us&edition=fundamental","pubTime":"2025-10-02 19:00","pubTimestamp":1759402842,"startTime":"0","endTime":"0","summary":"CytoMed Therapeutics Announces Promising Preclinical Results for Allogeneic γδ T Cell Therapy in Acute Myeloid Leukemia, Plans Clinical Trials in Southeast Asia. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cytomed Therapeutics Ltd. published the original content used to generate this news brief via GlobeNewswire  on October 02, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251002:nNDL1J8wdD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","GDTC","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","IE00BKPKM429.USD","LU2095319765.USD","IE00B64PRP62.GBP","BK4139","LU2210149790.SGD","NDAQ","BK4112","BK4585","LU2210150020.SGD","LU0314104364.USD"],"gpt_icon":0},{"id":"2570074460","title":"CytoMed Therapeutics Ltd  expected to post a loss of 3 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2570074460","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2570074460?lang=en_us&edition=fundamental","pubTime":"2025-09-26 19:07","pubTimestamp":1758884840,"startTime":"0","endTime":"0","summary":"CytoMed Therapeutics Ltd  expected to post a loss of3cents a share - Earnings Preview CytoMed Therapeutics Ltd GDTC.OQ, GDTC.O is expected to  show a rise in quarterly revenue when it reports  results","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250926:nL5N3VD0LW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GDTC","BK4139"],"gpt_icon":0},{"id":"2562030841","title":"CytoMed Therapeutics Ltd. Expands into Auto-Immune Disease Treatments Following Strategic Cord Blood Bank Acquisition","url":"https://stock-news.laohu8.com/highlight/detail?id=2562030841","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562030841?lang=en_us&edition=fundamental","pubTime":"2025-08-28 21:00","pubTimestamp":1756386042,"startTime":"0","endTime":"0","summary":"CytoMed Therapeutics Ltd., a clinical-stage biopharmaceutical company based in Singapore, has announced its expansion into the field of autoimmune diseases following its acquisition of a cord blood bank. The company has successfully scaled natural killer  cells from cryopreserved cord blood units, setting the stage for establishing a new business platform aimed at generating additional revenue and future growth. Under its restructured group, LongevityBank Pte Ltd will focus on autologous therapies, capitalizing on personalized cellular banking services. Meanwhile, CytoMed will continue to develop donor blood-derived allogeneic therapies, with ongoing clinical trials in Singapore and India. The strategic move positions LongevityBank to potentially spin off as an independent biopharmaceutical entity, concentrating on cord blood-derived treatments for autoimmune conditions. CytoMed anticipates that this expansion will contribute positively to its revenue, leveraging Asia's cost-effective ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250828:nNDL29qgvH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","IE00BKPKM429.USD","IE00BGHQF748.EUR","BK4112","BK4588","LU2210150020.SGD","LU2095319765.USD","BK4139","GDTC","IE00B64PRP62.GBP","NDAQ","LU2210149790.SGD","IE00B3QW5Z07.USD","LU0314104364.USD"],"gpt_icon":0},{"id":"2560130980","title":"CytoMed Therapeutics Limited Announces At-the-Market (ATM) Offering Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2560130980","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560130980?lang=en_us&edition=fundamental","pubTime":"2025-08-19 09:00","pubTimestamp":1755565200,"startTime":"0","endTime":"0","summary":"SINGAPORE, Aug.  18, 2025  (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing it","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/08/19/3135384/0/en/CytoMed-Therapeutics-Limited-Announces-At-the-Market-ATM-Offering-Program.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GDTC"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":17,"code":"91000000","status":"200"}]}}